Breaking News
Sort by:
Top Post
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial for the Treatment of Rett Syndrome
Taysha Gene Therapies, a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene […]
Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder
Sunovion Pharmaceuticals and Otsuka Pharmaceutical Development & Commercialization today announced that the first patient has […]
Alentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study
Alentis Therapeutics, the clinical-stage biotechnology company developing breakthrough treatments for organ fibrosis and CLDN1+ tumors, […]
National Multicenter Trial Opens to Study ImmunityBio’s Tri-Ad5 Cancer Vaccines Plus N-803 to Prevent Cancer in People with Lynch Syndrome
ImmunityBio, a clinical-stage immunotherapy company, today announced the opening of a clinical trial to study […]
Eplontersen Halted ATTRv-PN Disease Progression and Improved Neuropathy Impairment and Quality of Life in Study
Ionis Pharmaceuticals today announced that the Phase 3 NEURO-TTRansform study for AstraZeneca and Ionis’ eplontersen […]
Fractyl Health Announces the Initiation of a Global Registry Study of the Revita System™ in Patients With Inadequately Controlled Type 2 Diabetes (T2D)
Fractyl Health, a commercial-stage organ-editing metabolic therapeutics company focused on pioneering new approaches for the […]
Daewoong Pharmaceutical Announce Publication of Phase 3 Study of 'Envlo', a New Treatment for Diabetes
The research results of a Daewoong Pharmaceutical SGLT-2 inhibitor new drug for diabetes, ‘Envlo’, have been […]
MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease
MaaT Pharma, a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem […]
CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)
CymaBay Therapeutics, a biopharmaceutical company focused on developing and providing access to innovative therapies for […]
Life Biosciences Presents Groundbreaking Data at ARVO Demonstrating Restoration of Visual Function in Nonhuman Primates
Life Biosciences (Life Bio), a biotechnology company advancing innovative cellular rejuvenation technologies to reverse diseases […]
CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)
CymaBay Therapeutics, a biopharmaceutical company focused on developing and providing access to innovative therapies for […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more